PM.20.042 – FibroTheranostics: Theranostics for the diagnosis and treatment of fibrosis-driven organ failure

Route: Personalised medicine: the individual at the centre

Cluster question: 104 How do we develop minimally invasive techniques and interventions for diagnosis, prognosis, and treatment?

The mission of the FibroTheranostics is to diagnose and treat fibrosis-driven organ failure. Fibrosis affects millions of people worldwide, accounting for 45% of total deaths. With an aging population and increasing prevalence of viral infections, obesity and diabetes, the incidence of fibrotic diseases and subsequently the number of fibrosis-related deaths will rise exponentially. Fibrosis is a common outcome of many chronic diseases i.e. liver (liver fibrosis), kidney (kidney fibrosis), lungs (lung fibrosis) and heart (cardiac fibrosis) leading to end-stage organ failure. Currently, there are no viable therapies available to reverse chronic fibrosis. Organ transplantation is the only option available for these patients but organ shortage and chronic rejection limit the feasibility. Another major problem is timely, accurate and non-invasive diagnosis. With our unique consortium consisting of expert researchers (fundamental and nanotechnology focused), clinicians and pharma’s, we aim at development of innovative theranostics i.e. cell-selective targeted drug delivery systems that can be used for both the therapy and diagnostics of major fibrotic diseases namely liver, lung and kidney fibrosis. Our FibroTheranostics project will pave the way for a greater implementation of theranostics in healthcare, generating tools and knowledge for advanced personalized and regenerative therapies with a significant societal impact for both the scientific community and patients.


fibrosis, non-invasive diagnosis, Organ failure, Personalized medicine, theranostics


Organisation University of Twente (UT)
Name Dr. R. (Ruchi) Bansal